Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Melanoma 3Carcinoma, Renal Cell 2Uveal Melanoma 1Urologic Neoplasms 1Skin Neoplasms 1Neoplasms 1Leukemia, Promyelocytic, Acute 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia 1Kidney Neoplasms 1

Interventions

Cytarabine 33Etoposide 16Daunorubicin 16tipifarnib 10Mitoxantrone 10Idarubicin 9Azacitidine 8alvocidib 6Filgrastim 6Busulfan 6Peripheral Blood Stem Cell Transplantation 5valspodar 4Sorafenib 4Bortezomib 4fludarabine phosphate 3entinostat 3aldesleukin 3Vorinostat 3Tretinoin 3Radiotherapy 3Lenalidomide 3Gemtuzumab 3Decitabine 3Cyclophosphamide 3veliparib 2tanespimycin 2sargramostim 2lintuzumab 2laromustine 2Watchful Waiting 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Leukemia, Myelomonocytic, Acute × flt3 ligand protein × Clear all
NCT00006223 2013-06-24

flt3L in Treating Patients With Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 3 Completed
Other hematologic neoplasm

Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡